{"id":"azd8835-in-combination-with-fulvestrant","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"status":"active","trials":["NCT02260661"],"aliases":["Faslodex"],"patents":[],"pricing":[],"timeline":[],"aiSummary":"AZD8835 is a selective and potent inhibitor of the androgen receptor. Used for Hormone receptor-positive breast cancer.","brandName":"AZD8835 in combination with fulvestrant","companyId":"astrazeneca","mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD8835 works by blocking the androgen receptor, which is a key driver of hormone receptor-positive breast cancer. This leads to a decrease in tumor growth and proliferation.","oneSentence":"AZD8835 is a selective and potent inhibitor of the androgen receptor.","_ai_confidence":"high"},"commercial":null,"companyName":"AstraZeneca","competitors":[],"genericName":"AZD8835 in combination with fulvestrant","indications":{"approved":[{"name":"Hormone receptor-positive breast cancer"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}